These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 36896828)
1. Predictors of recurrence after paclitaxel drug-coated balloon use for treating femoropopliteal in-stent restenosis. Taha AG; Saleh MI; Ali H; Gamal WM Vascular; 2024 Aug; 32(4):834-841. PubMed ID: 36896828 [TBL] [Abstract][Full Text] [Related]
2. Drug-Coated Balloon for the Treatment of Femoropopliteal Tosaka Class III In-stent Restenosis Lesions. Zhang B; Niu G; Yan Z; Zou Y; Tong X; Yang M Front Surg; 2020; 7():616414. PubMed ID: 33521048 [No Abstract] [Full Text] [Related]
3. Paclitaxel-Eluting Balloon vs Standard Angioplasty to Reduce Restenosis in Diabetic Patients With In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Arteries: Three-Year Results of the DEBATE-ISR Study. Grotti S; Liistro F; Angioli P; Ducci K; Falsini G; Porto I; Ricci L; Ventoruzzo G; Turini F; Bellandi G; Bolognese L J Endovasc Ther; 2016 Feb; 23(1):52-7. PubMed ID: 26511896 [TBL] [Abstract][Full Text] [Related]
4. Outcomes and Comparative Analysis of the Initial Results of Standard Balloon Angioplasty Versus Drug-Coated Balloons Alone Versus in Association With Laser-Excimer Atherectomy in the Treatment of Femoropopliteal Artery In-Stent Restenosis (INTACT). Ducasse E; Sapoval M; Brunet J; Commeau P; Goueffic Y; Sabatier J; Steinmetz E; Lermusiaux P; Rosset E; Caradu C J Endovasc Ther; 2024 Apr; ():15266028241248333. PubMed ID: 38659343 [TBL] [Abstract][Full Text] [Related]
5. Drug-Coated Balloon Treatment for Femoropopliteal Artery Disease: The IN.PACT Global Study De Novo In-Stent Restenosis Imaging Cohort. Brodmann M; Keirse K; Scheinert D; Spak L; Jaff MR; Schmahl R; Li P; Zeller T; JACC Cardiovasc Interv; 2017 Oct; 10(20):2113-2123. PubMed ID: 29050631 [TBL] [Abstract][Full Text] [Related]
6. Randomized controlled study of excimer laser atherectomy for treatment of femoropopliteal in-stent restenosis: initial results from the EXCITE ISR trial (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis). Dippel EJ; Makam P; Kovach R; George JC; Patlola R; Metzger DC; Mena-Hurtado C; Beasley R; Soukas P; Colon-Hernandez PJ; Stark MA; Walker C; JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt A):92-101. PubMed ID: 25499305 [TBL] [Abstract][Full Text] [Related]
7. Percutaneous Mechanical Atherectomy Plus Thrombectomy Using the Rotarex®S Device Followed by a Drug-Coated Balloon for the Treatment of Femoropopliteal Artery In-stent Restenosis: A Prospective Single-Center, Single-Arm Efficacy Trial (PERMIT-ISR Trial). Liu MY; Li W; Guo X; Zhang Z; Liu B; Yu H; Zhang Z; Chen X; Feng H Front Surg; 2021; 8():671849. PubMed ID: 34595204 [No Abstract] [Full Text] [Related]
8. Debulking plus drug-coated balloon angioplasty versus drug-coated balloon angioplasty alone for femoropopliteal Tosaka III in-stent restenosis lesions. Li L; Tong Z; Cui S; Guo L Wideochir Inne Tech Maloinwazyjne; 2023 Mar; 18(1):166-172. PubMed ID: 37064559 [TBL] [Abstract][Full Text] [Related]
9. Laser Atherectomy Combined With Drug-Coated Balloon Angioplasty Is Associated With Improved 1-Year Outcomes for Treatment of Femoropopliteal In-Stent Restenosis. Kokkinidis DG; Hossain P; Jawaid O; Alvandi B; Foley TR; Singh GD; Waldo SW; Laird JR; Armstrong EJ J Endovasc Ther; 2018 Feb; 25(1):81-88. PubMed ID: 29219030 [TBL] [Abstract][Full Text] [Related]